Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 21 years of age or older.
- You are able to follow simple instructions during an eye imaging scan (similar to a standard eye exam).
- You are able to understand and sign a consent form agreeing to take part.
- You have been diagnosed with primary open-angle glaucoma, also known as POAG (for one specific group in the trial).
Who may not be able to join:
- You are under 21 years of age.
- You have an eye condition that would prevent clear images from being taken, such as difficulty keeping your eye still or cloudiness in the eye (confirm with trial site).
- Your eyeglass or contact lens prescription is stronger than +4 or weaker than -8 (confirm with trial site).
- You have had a bad reaction to eye drops that dilate your pupils in the past.
- You have a narrow drainage angle in your eye or have ever had a sudden, painful type of glaucoma called acute angle closure glaucoma.
- You do not meet the specific medical definition of primary open-angle glaucoma set by the American Academy of Ophthalmology (for one specific group in the trial).
- You have a lung or breathing condition such as COPD, emphysema, or asthma that would make it unsafe to receive extra oxygen — this applies only to participants in a specific part of the trial involving blood flow measurements.
- You rely on oxygen support to breathe, or your blood oxygen level is below 95% — this applies only to participants in the blood flow measurement part of the trial.
- You have tested positive for COVID-19 at the time of joining, or you have ongoing light sensitivity as a result of having had COVID-19.
- You work directly under the supervision of Dr. Hammer.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel X Hammer, Ph.D., Food and Drug Administration (FDA)
Phone: 301-796-9320
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Retinal blood flow (RBF) with oxygen inhalation; Retinal ganglion cell (RGC) density; RGC soma diameter; Retinal pigment epithelium (RPE) cell organelle motility; Photoreceptor (PR) cell function
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.